

# Girish Dhall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4749991/publications.pdf>

Version: 2024-02-01

43  
papers

1,552  
citations

430874

18  
h-index

315739

38  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2752  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1011-1022.	10.7	315
2	Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1169-1175.	1.5	206
3	Medulloblastoma. <i>Journal of Child Neurology</i> , 2009, 24, 1418-1430.	1.4	112
4	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	1.5	94
5	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. <i>Clinical Cancer Research</i> , 2015, 21, 1457-1465.	7.0	92
6	Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. <i>Pediatric Blood and Cancer</i> , 2008, 50, 72-79.	1.5	80
7	Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3283-3290.	1.6	78
8	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 443-451.	2.9	69
9	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2016, 18, 126-131.	1.2	69
10	Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. <i>Oncotarget</i> , 2019, 10, 551-557.	1.8	44
11	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
12	Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. <i>Pediatric Blood and Cancer</i> , 2016, 63, 527-534.	1.5	38
13	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. <i>Journal of Neuro-Oncology</i> , 2017, 133, 119-128.	2.9	32
14	Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1806-1813.	1.5	29
15	Allergic reactions and anti-asparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. <i>Cancer</i> , 2015, 121, 4205-4211.	4.1	28
16	Changes in Signal Intensity of the Dentate Nucleus and Globus Pallidus in Pediatric Patients: Impact of Brain Irradiation and Presence of Primary Brain Tumors Independent of Linear Gadolinium-based Contrast Agent Administration. <i>Radiology</i> , 2018, 287, 452-460.	7.3	27
17	Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy. <i>Oncotarget</i> , 2017, 8, 114210-114225.	1.8	25
18	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2020, 147, 721-730.	2.9	21

#	ARTICLE	IF	CITATIONS
19	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. <i>Cancer Research</i> , 2019, 79, 2208-2219.	0.9	15
20	Brain Irradiation and Gadobutrol Administration in Pediatric Patients with Brain Tumors: Effect on MRI Brain Signal Intensity. <i>Radiology</i> , 2018, 289, 188-194.	7.3	12
21	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 1950-1961.	1.2	12
22	Pregnancy in a Patient With a Malignant Brain Tumor Taking Temozolomide. <i>Journal of Pediatric Oncology Nursing</i> , 2015, 32, 326-328.	1.5	11
23	A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10504-10504.	1.6	11
24	Relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated without irradiation: Findings from the Third International Central Nervous System (CNS) Germ Cell Tumor (GCT) Study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1920-1924.	1.5	10
25	A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. <i>Journal of Neuro-Oncology</i> , 2018, 140, 575-582.	2.9	9
26	Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27983.	1.5	9
27	Long-term follow-up of endocrine function among young children with newly diagnosed malignant central nervous system tumors treated with irradiation-avoiding regimens. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26616.	1.5	8
28	Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002576.	1.2	8
29	Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. <i>Journal of Neuro-Oncology</i> , 2018, 138, 199-207.	2.9	7
30	Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26878.	1.5	7
31	Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27920.	1.5	7
32	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. <i>Journal of Neuro-Oncology</i> , 2019, 145, 375-383.	2.9	7
33	A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27217.	1.5	6
34	Corrigendum to: LTBK-01. Updates On The Phase II And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. <i>Neuro-Oncology</i> , 2022, 24, 1404-1404.	1.2	5
35	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab037.	0.7	3
36	False-positive magnetic resonance imaging findings in follow-up of pediatric patients with tumors of the central nervous system. <i>SAGE Open Medical Case Reports</i> , 2016, 4, 2050313X1666623.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Radiotherapy after high-dose chemotherapy with autologous hematopoietic cell rescue: Quality assessment of Head Start III. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26529.	1.5	2
38	GC-20 THE CHILDREN'S ONCOLOGY GROUP (COG) CURRENT TREATMENT APPROACH FOR CHILDREN WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM (CNS) NON-GERMINOMATOUS GERM CELL TUMORS (NGGCTs). <i>Neuro-Oncology</i> , 2016, 18, iii46.3-iii46.	1.2	1
39	Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26329.	1.5	1
40	MB-34 * MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IDENTIFICATION USING NON-INVASIVE MAGNETIC RESONANCE SPECTROSCOPY. <i>Neuro-Oncology</i> , 2015, 17, iii27-iii27.	1.2	0
41	MB-101 TOXICITY AND OUTCOME IN ADOLESCENT AND YOUNG ADULTS (AYA) TREATED FOR MEDULLOBLASTOMA (MB) AND PRIMITIVE NEUROECTODERMAL TUMORS (PNET) ON COG-A9961 AND CCG-99701: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG). <i>Neuro-Oncology</i> , 2016, 18, iii120.1-iii120.	1.2	0
42	AT-23 ENCOURAGING SURVIVAL OF PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID AND RHABDOID TUMOR (AT/RT) TREATED AS PER CHILDREN'S ONCOLOGY GROUP ACNS0333 STUDY: A SINGLE-INSTITUTION EXPERIENCE. <i>Neuro-Oncology</i> , 2016, 18, iii6.3-iii6.	1.2	0
43	Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961. <i>Blood</i> , 2009, 114, 3077-3077.	1.4	0